Rituximab therapy and autoimmune disorders: Prospects for anti-B cell therapy

Arthritis and Rheumatism

Volumn 48, Issue 6, 2003, Pages 1484-1492

  Silverman, Gregg J ^a   Weisman, Stuart ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DNA ANTIBODY; DOXORUBICIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PREDNISOLONE; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; STAPHYLOCOCCUS PROTEIN A; VINCRISTINE;

AUTOIMMUNITY; B CELL LYMPHOMA; B LYMPHOCYTE; CHILL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE DIFFERENTIATION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOMA, B-CELL; MICE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECOMBINANT FUSION PROTEINS;

EID: 0037638841     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10947     Document Type: Review

References (64)

1. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980;125:1678-85.
2. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics 1998;48:125-32.
3. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711-7.
4. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15:450-4.
5. Kanzaki M, Shibata H, Mogami H, Kojima I. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem 1995;270:13099-104.
6. Golay JT, Clark EA, Beverley PC. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 1985;135:3795-801.
7. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987;69:584-91.
8. Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, et al. Binding to CD20 by anti-B1 antibody or F(ab′)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002;51:15-24.
9. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
10. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets [see comments]. Nat Med 2000;6:443-6.
11. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001;61:5137-44.
12. Deans JP, Schieven GL, Shu GL, Valentine MA, Gilliland LA, Aruffo A, et al. Association of tyrosine and serine kinases with the B cell surface antigen CD20: induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. J Immunol 1993;151:4494-504.
13. Mathas S, Rickers A, Bommert K, Dorken B, Mapara MY. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2000;60:7170-6.
14. Grillo-Lopez AJ. Rituximab: an insider's historical perspective. Semin Oncol 2000;27 Suppl 12:9-16.
15. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998;10:548-51.
16. Czuczman MS. Combination chemotherapy and rituximab. Anticancer Drugs 2001;12 Suppl 2:S15-9.
17. Johnson PW, Glennie MJ. Rituximab: mechanisms and applications. Br J Cancer 2001;85:1619-23.
18. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol 2000;18:3135-43.
19. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003. In press.
20. Patel DD. B cell-ablative therapy for the treatment of autoimmune diseases. Arthritis Rheum 2002;46:1984-5.
21. Looney RJ. Treating human autoimmune disease by depleting B cells. Ann Rheum Dis 2002;61:863-6.
22. Karpatkin S. Autoimmune thrombocytopenic purpura. Semin Hematol 1985;22:260-88.
23. Saleh MN, Gutheil J, Moore M, Bunch PW, Butler J, Kunkel L, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000;27 Suppl 12:99-103.
24. Stasi R, Stipa E, Forte V, Meo P, Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002;99:3872-3.
25. Anolik JH, Campbell D, Ritchlin C, Holyst M, Rosenfeld S, Varnis C, et al. B lymphocyte depletion as a novel treatment for systemic lupus erythematosus (SLE): phase I/II trial of rituximab (Rituxan) in SLE [abstract]. Arthritis Rheum 2001;44 Suppl 9:S387.
26. Anolik JH, Campbell D, Felgar R, Rosenblatt J, Young F, Looney RJ. B lymphocyte depletion in the treatment of systemic lupus (SLE): phase I/II trial of rituximab in SLE [abstract]. Arthritis Rheum 2002;46 Suppl 9:S717.
27. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7.
28. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11.
29. Felson DT, Anderson JJ, Lange MLM, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures rather than twenty percent? Arthritis Rheum 1998;41:1564-70.
30. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.
31. Leandro MJ, Edwards JCW, Cambridge G. B lymphocyte depletion in rheumatoid arthritis: early evidence for safety, efficacy, and dose response [abstract]. Arthritis Rheum 2001;44 Suppl 9:S370.
32. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
33. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Close D, Stevens RM, et al. Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo-controlled trial in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2002;46 Suppl 9:S446.
34. DeVita SD, Zaja F, Sacco S, Candia AD, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002;46:2029-33.
35. Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999;169:107-21.
36. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-8.
37. Alwayn IP, Xu Y, Basker M, Wu C, Buhler L, Lambrigts D, et al. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody. Xenotransplantation 2001;8:157-71.
38. O'Connor BP, Cascalho M, Noelle RJ. Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J Exp Med 2002;195:737-45.
39. McHeyzer-Williams MG, Ahmed R. B cell memory and the long-lived plasma cell. Curr Opin Immunol 1999;11:172-9.
40. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001;294:1540-3.
41. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 2001;167:2361-9.
42. Marinova-Mutafchieva L, Williams RO, Funa K, Maini RN, Zvaifler NJ. Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum 2002;46:507-13.
43. Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest 2001;107:305-15.
44. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993;261:1328-30.
45. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995;154:1470-80.
46. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7.
47. Mackay F, Mackay CR. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity. Trends Immunol 2002;23:113-5.
48. Silverman GJ, Cary SP, Dwyer DC, Luo L, Wagenknecht R, Curtiss VE. A B cell superantigen-induced persistent "Hole" in the B-1 repertoire. J Exp Med 2000;192:87-98.
49. Goodyear CS, Silverman GJ. Death by a B-cell superantigen: in vivo VH targeted apoptotic supra-clonal B-cell deletion by a staphylococcal toxin. J Exp Med. In press.
50. Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002;87:189-95.
51. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:1511-3.
52. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002;61:922-4.
53. Ahrens N, Kingreen D, Seltsam A, Salama A. Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). Br J Haematol 2001;114:244-5.
54. Morselli M, Luppi M, Potenza L, Tonelli S, Dini D, Leonardi G, et al. Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment. Blood 2002;99:3478-9.
55. Zaja F, Russo D, Fuga G, Michelutti T, Sperotto A, Fanin R, et al. Rituximab in a case of cold agglutinin disease. Br J Haematol 2001;115:232-3.
56. Berentsen S, Tjonnfjord GE, Brudevold R, Gjertsen BT, Langholm R, Lokkevik E, et al. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol 2001;115:79-83.
57. Sparling TG, Andricevic M, Wass H. Remission of cold hemagglutinin disease induced by rituximab therapy [letter]. Can Med Assoc J 2001;164:1405.
58. Layios N, Van Den Neste E, Jost E, Deneys V, Scheiff JM, Ferrant A. Remission of severe cold agglutinin disease after rituximab therapy. Leukemia 2001;15:187-8.
59. Zaja F, Russo D, Fuga G, Patriarca F, Ermacora A, Baccarani M. Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 1999;84:1157-8.
60. DeVita S, Zaja F, Sacco S, Michelutti A, DeMarchi G, Mazzaro C, et al. Efficacy and safety of rituximab treatment in type II 11 mixed cryoglobulinemia [abstract]. Arthritis Rheum 2002;46 Suppl 9:S206.
61. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999;52:1701-4.
62. Zaja F, Russo D, Fuga G, Perella G, Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000;55:1062-3.
63. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:2836-40.
64. Levine TD. A pilot study of rituximab therapy for refractory dermatomyositis [abstract]. Arthritis Rheum 2002;46 Suppl 9:S488.